Review



recombinant human scd40 ligand  (PeproTech)


Bioz Verified Symbol PeproTech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    PeproTech recombinant human scd40 ligand
    Recombinant Human Scd40 Ligand, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pm39609395-268-78-82
    Average 90 stars, based on 1 article reviews
    recombinant human scd40 ligand - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Additive channels
    Article Snippet: ECM Coating APTES 1% (Sigma 281778), 10 ul/ml ethanol Rat tail collagen I 100 μg/mL (Corning 354249) For Outflow chip: 0.5 mg/ml of ER1 in 50 mM of ER2 for 20 min under UV, Rat tail collagen I 100 μg/ml (corning 354249) CELLS Main Human Umbilical Vein Endothelial Cells Channel at P5/P6 (HUVEC, pooled; Lonza C2519A) MEDIA EGM-2 EGM-2 SingleQuot kit (without GA) in 500 mL bottle of EBM-2 (Lonza CC-3162) + 1% P/S CHIP Thrombosis 6 parallel 400 um wide, Chip 100 um tall channels, 3.5 mm large inlets Reservoirs 5 mL syringes Tubing Tygon E-3603 1/16′′ ID tubing for blood experiments Connecters Nylon barbed straight connectors for blood experiments (McMaster 5463K36) EXPERIMENTAL REAGENTS Blood Fresh human blood in 3.2% citrate vacutainer (Research Blood Components, Cambridge, MA) Ca/Mg 10X calcium/magnesium solution solution (100 mM calcium chloride/75 mM magnesium chloride) sCD40L Recombinant human sCD40 Ligand (PeproTech 310-02) CD41 CD41 Mouse Anti-Human mAb (clone VIPL3), PE Conjugate (Invitrogen MHCD4104) IV.3 Anti-Human CD32 Antibody, Clone IV.3, FITC (Stemcell Technologies 60012F1) Fibrinogen Fibrinogen from Human Plasma, Conjugated (Life Technologies F13191/ F35200) TNF-α Tumor Necrosis Factor-α human (Sigma T6674) Chip Coating 1.

    Recombinant:

    Article Title: Adaptation in human immune cells residing in tissues at the frontline of infections
    Article Snippet: .. As described in the study, iPSCs were differentiated to macrophages and stimulated for 6 h and 24 h with 10 ng/mL recombinant human interleukin-10 (Peprotech, 200-10-2), 10 ng/mL recombinant human interferon-b (Peprotech, 300-02BC-5), 20 ng/mL recombinant human interleukin-4 (Peprotech, 200-04-5), 50 ng/mL P3C (Pam3CSK4) (Tocris, 4633/1), 20 ng/mL recombinant human interferon- γ (Peprotech, 300-02-20), 10 ng/mL lipopolysaccharides from Escherichia coli O127:B8 (Sigma Aldrich, L3129), 40 ng/mL human recombinant tumour necrosis factor alpha (Peprotech, 300-01A-10), 100 ng/mL R848 (Resiquimod) (Invivogen, tlrl-r848), or 5 ng/mL recombinant human sCD40 Ligand (Peprotech, 310-02-10), 27.5 μg/ml poly I:C (Invivogen, tlrl-pic, diluted in Lipofectamine -Thermo Fisher, L3000001- and Opti-MEM media -Thermo Fisher, 31985062-) as described in ref. . RNA libraries were obtained using the low-input bulk RNA-seq preparation for control and stimulated macrophage samples . ..

    Article Title: Class Switch Recombination Occurs Infrequently in Germinal Centers
    Article Snippet: Recombinant Murine IL-4 , PeproTech Inc. , Cat#214–14. .. Recombinant Human sCD40 Ligand , PeproTech Inc. , Cat#310–02. .. RIPA buffer , Thermo Fisher , Cat#89901.

    Article Title: Gene expression QTL mapping in stimulated iPSC-derived macrophages provides insights into common complex diseases
    Article Snippet: .. After the 7-day differentiation to macrophages, cells were incubated for 6 or 24 hours in complete macrophage media on its own (controls) or containing the following stimuli: : 10 ng/mL recombinant human interleukin-10 (Peprotech, 200-10-2), 10 ng/mL recombinant human interferon-b (Peprotech, 300-02BC-5), 20 ng/mL recombinant human interleukin-4 (Peprotech, 200-04-5), 50 ng/mL P3C (Pam3CSK4) (Tocris, 4633/1), 20 ng/mL recombinant human interferon-γ (Peprotech, 300-02-20), 10 ng/mL lipopolysaccharides from Escherichia coli O127:B8 (Sigma Aldrich, L3129), 40 ng/mL human recombinant tumour necrosis factor alpha (Peprotech, 300-01A-10), 100 ng/mL R848 (Resiquimod) (Invivogen, tlrl-r848), or 5 ng/mL recombinant human sCD40 Ligand (Peprotech, 310-02-10). .. For the stimulations with HMW poly I:C (Invivogen, tlrl-pic), macrophages were transfected with poly I:C as follows: 0.15 mL of 1 mg/mL of poly I:C was mixed with 0.3 mL P3000 reagent (Lipofectamine 3000 kit) and 5 mL Opti-MEM (Thermo Fisher, 31985062).

    Article Title: Adaptation in human immune cells residing in tissues at the frontline of infections.
    Article Snippet: .. As described in the study, iPSCs were differentiated to macrophages76 and stimulated for 6 h and 24 h with 10 ng/mL recombinant human interleukin-10 (Peprotech, 200-10-2), 10 ng/mL recombinant human interferon-b (Peprotech, 300-02BC-5), 20 ng/mL recombinant human interleukin-4 (Peprotech, 200-04-5), 50ng/mL P3C (Pam3CSK4) (Tocris, 4633/1), 20 ng/mL recombinant human interferon-γ (Peprotech, 300-02-20), 10 ng/mL lipopolysaccharides fromEscherichia coli O127:B8 (SigmaAldrich, L3129), 40 ng/mLhuman recombinant tumour necrosis factor alpha (Peprotech, 300-01A-10), 100 ng/mL R848 (Resiquimod) (Invivogen, tlrl-r848), or 5 ng/mL recombinant human sCD40 Ligand (Peprotech, 310-02-10), 27.5 μg/ml poly I:C (Invivogen, tlrl-pic, diluted in Lipofectamine -Thermo Fisher, L3000001- and Opti-MEM media -Thermo Fisher, 31985062-) as described in ref. 55. ..

    RNA Sequencing:

    Article Title: Adaptation in human immune cells residing in tissues at the frontline of infections
    Article Snippet: .. As described in the study, iPSCs were differentiated to macrophages and stimulated for 6 h and 24 h with 10 ng/mL recombinant human interleukin-10 (Peprotech, 200-10-2), 10 ng/mL recombinant human interferon-b (Peprotech, 300-02BC-5), 20 ng/mL recombinant human interleukin-4 (Peprotech, 200-04-5), 50 ng/mL P3C (Pam3CSK4) (Tocris, 4633/1), 20 ng/mL recombinant human interferon- γ (Peprotech, 300-02-20), 10 ng/mL lipopolysaccharides from Escherichia coli O127:B8 (Sigma Aldrich, L3129), 40 ng/mL human recombinant tumour necrosis factor alpha (Peprotech, 300-01A-10), 100 ng/mL R848 (Resiquimod) (Invivogen, tlrl-r848), or 5 ng/mL recombinant human sCD40 Ligand (Peprotech, 310-02-10), 27.5 μg/ml poly I:C (Invivogen, tlrl-pic, diluted in Lipofectamine -Thermo Fisher, L3000001- and Opti-MEM media -Thermo Fisher, 31985062-) as described in ref. . RNA libraries were obtained using the low-input bulk RNA-seq preparation for control and stimulated macrophage samples . ..

    Control:

    Article Title: Adaptation in human immune cells residing in tissues at the frontline of infections
    Article Snippet: .. As described in the study, iPSCs were differentiated to macrophages and stimulated for 6 h and 24 h with 10 ng/mL recombinant human interleukin-10 (Peprotech, 200-10-2), 10 ng/mL recombinant human interferon-b (Peprotech, 300-02BC-5), 20 ng/mL recombinant human interleukin-4 (Peprotech, 200-04-5), 50 ng/mL P3C (Pam3CSK4) (Tocris, 4633/1), 20 ng/mL recombinant human interferon- γ (Peprotech, 300-02-20), 10 ng/mL lipopolysaccharides from Escherichia coli O127:B8 (Sigma Aldrich, L3129), 40 ng/mL human recombinant tumour necrosis factor alpha (Peprotech, 300-01A-10), 100 ng/mL R848 (Resiquimod) (Invivogen, tlrl-r848), or 5 ng/mL recombinant human sCD40 Ligand (Peprotech, 310-02-10), 27.5 μg/ml poly I:C (Invivogen, tlrl-pic, diluted in Lipofectamine -Thermo Fisher, L3000001- and Opti-MEM media -Thermo Fisher, 31985062-) as described in ref. . RNA libraries were obtained using the low-input bulk RNA-seq preparation for control and stimulated macrophage samples . ..

    Incubation:

    Article Title: Gene expression QTL mapping in stimulated iPSC-derived macrophages provides insights into common complex diseases
    Article Snippet: .. After the 7-day differentiation to macrophages, cells were incubated for 6 or 24 hours in complete macrophage media on its own (controls) or containing the following stimuli: : 10 ng/mL recombinant human interleukin-10 (Peprotech, 200-10-2), 10 ng/mL recombinant human interferon-b (Peprotech, 300-02BC-5), 20 ng/mL recombinant human interleukin-4 (Peprotech, 200-04-5), 50 ng/mL P3C (Pam3CSK4) (Tocris, 4633/1), 20 ng/mL recombinant human interferon-γ (Peprotech, 300-02-20), 10 ng/mL lipopolysaccharides from Escherichia coli O127:B8 (Sigma Aldrich, L3129), 40 ng/mL human recombinant tumour necrosis factor alpha (Peprotech, 300-01A-10), 100 ng/mL R848 (Resiquimod) (Invivogen, tlrl-r848), or 5 ng/mL recombinant human sCD40 Ligand (Peprotech, 310-02-10). .. For the stimulations with HMW poly I:C (Invivogen, tlrl-pic), macrophages were transfected with poly I:C as follows: 0.15 mL of 1 mg/mL of poly I:C was mixed with 0.3 mL P3000 reagent (Lipofectamine 3000 kit) and 5 mL Opti-MEM (Thermo Fisher, 31985062).



    Similar Products

    recombinant human scd40 ligand  (PeproTech)
    90
    PeproTech recombinant human scd40 ligand
    Recombinant Human Scd40 Ligand, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pm39609395-268-78-82
    Average 90 stars, based on 1 article reviews
    recombinant human scd40 ligand - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human (rh) scd40 ligand  (PeproTech)
    90
    PeproTech recombinant human (rh) scd40 ligand
    Recombinant Human (Rh) Scd40 Ligand, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pmc11110724-39-14-19
    Average 90 stars, based on 1 article reviews
    recombinant human (rh) scd40 ligand - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human scd40 ligand (cd40l)  (PeproTech)
    90
    PeproTech recombinant human scd40 ligand (cd40l)
    Recombinant Human Scd40 Ligand (Cd40l), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pm36155926-34-11-16
    Average 90 stars, based on 1 article reviews
    recombinant human scd40 ligand (cd40l) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human scd40 ligand scd40l 310-02  (PeproTech)
    90
    PeproTech recombinant human scd40 ligand scd40l 310-02
    Recombinant Human Scd40 Ligand Scd40l 310 02, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pm36209148-61-0-8
    Average 90 stars, based on 1 article reviews
    recombinant human scd40 ligand scd40l 310-02 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human scd40 ligand (scd40l; 310-02)  (PeproTech)
    90
    PeproTech recombinant human scd40 ligand (scd40l; 310-02)
    a Diverse stimulants abrogate venetoclax cytotoxicity against patient-derived CLL cells. Primary cells (1 × 10 6 cells/mL) obtained from nine patients with CLL were treated with 0.1% DMSO (vehicle control), and 1 nM venetoclax alone and in combination with 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL <t>sCD40L</t> for 24 h. The metabolic activities of the cells were determined using the PrestoBlue assay. Data are means ± SEM of ≥ three independent experiments, each carried out in duplicate. Two-way ANOVA (post hoc Tukey); *, **, and **** denote p < 0.05, p < 0.01, and p < 0.0001, respectively; b Cytoprotective effects of IFNγ in the patient-derived CLL cells undergoing spontaneous and venetoclax-induced apoptosis. CLL cells (1 × 10 6 cells/mL) were treated with 0.1% DMSO (vehicle control) and 1 nM venetoclax, 100 ng/mL IFNγ, and their combination for 24 h. Apoptosis was assessed using the SYTOX Blue/annexin V assay. Representative dot plots (left) and means ± SEM of three independent experiments (right) are shown. Two-way ANOVA (post hoc Tukey); *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively; c Nuclear translocation of NFκB in the primary CLL cells. CLL cells (1 × 10 6 c ells/mL) from three patients with CLL were treated with 0.1% DMSO (vehicle control), 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 1 h. Quantification (left) and representative images (right) are shown for the translocation of NFκB to the nucleus, using imaging flow cytometry. One-way ANOVA (post hoc Dunnett); **** denotes p < 0.0001.
    Recombinant Human Scd40 Ligand (Scd40l; 310 02), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pmc09547871-56-0-8
    Average 90 stars, based on 1 article reviews
    recombinant human scd40 ligand (scd40l; 310-02) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human scd40-ligand  (PeproTech)
    90
    PeproTech recombinant human scd40-ligand
    a Diverse stimulants abrogate venetoclax cytotoxicity against patient-derived CLL cells. Primary cells (1 × 10 6 cells/mL) obtained from nine patients with CLL were treated with 0.1% DMSO (vehicle control), and 1 nM venetoclax alone and in combination with 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL <t>sCD40L</t> for 24 h. The metabolic activities of the cells were determined using the PrestoBlue assay. Data are means ± SEM of ≥ three independent experiments, each carried out in duplicate. Two-way ANOVA (post hoc Tukey); *, **, and **** denote p < 0.05, p < 0.01, and p < 0.0001, respectively; b Cytoprotective effects of IFNγ in the patient-derived CLL cells undergoing spontaneous and venetoclax-induced apoptosis. CLL cells (1 × 10 6 cells/mL) were treated with 0.1% DMSO (vehicle control) and 1 nM venetoclax, 100 ng/mL IFNγ, and their combination for 24 h. Apoptosis was assessed using the SYTOX Blue/annexin V assay. Representative dot plots (left) and means ± SEM of three independent experiments (right) are shown. Two-way ANOVA (post hoc Tukey); *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively; c Nuclear translocation of NFκB in the primary CLL cells. CLL cells (1 × 10 6 c ells/mL) from three patients with CLL were treated with 0.1% DMSO (vehicle control), 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 1 h. Quantification (left) and representative images (right) are shown for the translocation of NFκB to the nucleus, using imaging flow cytometry. One-way ANOVA (post hoc Dunnett); **** denotes p < 0.0001.
    Recombinant Human Scd40 Ligand, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+scd40+ligand/scd40+ligand/pm26719354-33-0-6
    Average 90 stars, based on 1 article reviews
    recombinant human scd40-ligand - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a Diverse stimulants abrogate venetoclax cytotoxicity against patient-derived CLL cells. Primary cells (1 × 10 6 cells/mL) obtained from nine patients with CLL were treated with 0.1% DMSO (vehicle control), and 1 nM venetoclax alone and in combination with 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 24 h. The metabolic activities of the cells were determined using the PrestoBlue assay. Data are means ± SEM of ≥ three independent experiments, each carried out in duplicate. Two-way ANOVA (post hoc Tukey); *, **, and **** denote p < 0.05, p < 0.01, and p < 0.0001, respectively; b Cytoprotective effects of IFNγ in the patient-derived CLL cells undergoing spontaneous and venetoclax-induced apoptosis. CLL cells (1 × 10 6 cells/mL) were treated with 0.1% DMSO (vehicle control) and 1 nM venetoclax, 100 ng/mL IFNγ, and their combination for 24 h. Apoptosis was assessed using the SYTOX Blue/annexin V assay. Representative dot plots (left) and means ± SEM of three independent experiments (right) are shown. Two-way ANOVA (post hoc Tukey); *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively; c Nuclear translocation of NFκB in the primary CLL cells. CLL cells (1 × 10 6 c ells/mL) from three patients with CLL were treated with 0.1% DMSO (vehicle control), 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 1 h. Quantification (left) and representative images (right) are shown for the translocation of NFκB to the nucleus, using imaging flow cytometry. One-way ANOVA (post hoc Dunnett); **** denotes p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

    doi: 10.1038/s41419-022-05287-6

    Figure Lengend Snippet: a Diverse stimulants abrogate venetoclax cytotoxicity against patient-derived CLL cells. Primary cells (1 × 10 6 cells/mL) obtained from nine patients with CLL were treated with 0.1% DMSO (vehicle control), and 1 nM venetoclax alone and in combination with 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 24 h. The metabolic activities of the cells were determined using the PrestoBlue assay. Data are means ± SEM of ≥ three independent experiments, each carried out in duplicate. Two-way ANOVA (post hoc Tukey); *, **, and **** denote p < 0.05, p < 0.01, and p < 0.0001, respectively; b Cytoprotective effects of IFNγ in the patient-derived CLL cells undergoing spontaneous and venetoclax-induced apoptosis. CLL cells (1 × 10 6 cells/mL) were treated with 0.1% DMSO (vehicle control) and 1 nM venetoclax, 100 ng/mL IFNγ, and their combination for 24 h. Apoptosis was assessed using the SYTOX Blue/annexin V assay. Representative dot plots (left) and means ± SEM of three independent experiments (right) are shown. Two-way ANOVA (post hoc Tukey); *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively; c Nuclear translocation of NFκB in the primary CLL cells. CLL cells (1 × 10 6 c ells/mL) from three patients with CLL were treated with 0.1% DMSO (vehicle control), 100 ng/mL IFNγ, 10 nM PMA/1 µM ionomycin, and 100 ng/mL sCD40L for 1 h. Quantification (left) and representative images (right) are shown for the translocation of NFκB to the nucleus, using imaging flow cytometry. One-way ANOVA (post hoc Dunnett); **** denotes p < 0.0001.

    Article Snippet: Recombinant human sCD40 ligand (sCD40L; 310-02) was from PeproTech (London, UK).

    Techniques: Derivative Assay, Prestoblue Assay, Annexin V Assay, Translocation Assay, Imaging, Flow Cytometry